Media
Press Releases
Contact Us
Home
Our Company
Leadership Team & Board of Directors
Our Pipeline
Nectin-4 Biology
Integrin Biology
CB1R Inverse Agonist Biology
Scientific Publications & Presentations
Scientific Conferences Attended
For Investors
Investor Relations
Overview
Corporate Presentation
Analyst Coverage
News / Events
Press Releases
Events
Company Info
Profile
IR Contacts
FAQ
Financial Info
Financials
Financial Results
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Docs
Join Us
Working Here
Benefits and Perks Packages
View Open Positions
Media
Press Releases
Contact Us
Connecting Innovation to Purpose
Latest News
Our Expanded Pipeline
View All News
Recent News
12/09/2024 • 7:00 AM EST
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
12/03/2024 • 7:00 AM EST
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
Investor Information
View Investor Relations
CRBP
Nasdaq
Volume
Market Cap
Change
Sign up for email alerts
Receive breaking news first.
Learn More
Investor presentation
View our latest investor presentation.
Download the pdf